{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T19:52:13Z","timestamp":1792525933263,"version":"4.5.0"},"reference-count":40,"publisher":"Wiley","issue":"9","license":[{"start":{"date-parts":[[2017,5,5]],"date-time":"2017-05-05T00:00:00Z","timestamp":1493942400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Novo Nordisk A\/S, S\u00f8borg, Denmark"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Diabetes Obesity Metabolism"],"published-print":{"date-parts":[[2017,9]]},"abstract":"<jats:sec>\n                    <jats:title>Aim<\/jats:title>\n                    <jats:p>The aim of this trial was to investigate the mechanism of action for body weight loss with semaglutide.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and methods<\/jats:title>\n                    <jats:p>\n                      This randomised, double\u2010blind, placebo\u2010controlled, two\u2010period crossover trial investigated the effects of 12\u2009weeks of treatment with once\u2010weekly subcutaneous semaglutide, dose\u2010escalated to 1.0\u2009mg, in 30 subjects with obesity.\n                      <jats:italic>Ad libitum<\/jats:italic>\n                      energy intake, ratings of appetite, thirst, nausea and well\u2010being, control of eating, food preference, resting metabolic rate, body weight and body composition were assessed.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      After a standardised breakfast, semaglutide, compared with placebo, led to a lower\n                      <jats:italic>ad libitum<\/jats:italic>\n                      energy intake during lunch (\u22121255\u2009\n                      <jats:styled-content style=\"fixed-case\">kJ<\/jats:styled-content>\n                      ;\n                      <jats:italic>\n                        <jats:styled-content style=\"fixed-case\">P<\/jats:styled-content>\n                      <\/jats:italic>\n                      \u2009&lt;\u2009.0001) and during the subsequent evening meal (\n                      <jats:italic>\n                        <jats:styled-content style=\"fixed-case\">P<\/jats:styled-content>\n                      <\/jats:italic>\n                      \u2009=\u2009.0401) and snacks (\n                      <jats:italic>\n                        <jats:styled-content style=\"fixed-case\">P<\/jats:styled-content>\n                      <\/jats:italic>\n                      \u2009=\u2009.0034), resulting in a 24% reduction in total energy intake across all\n                      <jats:italic>ad libitum<\/jats:italic>\n                      meals throughout the day (\u22123036\u2009\n                      <jats:styled-content style=\"fixed-case\">kJ<\/jats:styled-content>\n                      ;\n                      <jats:italic>\n                        <jats:styled-content style=\"fixed-case\">P<\/jats:styled-content>\n                      <\/jats:italic>\n                      \u2009&lt;\u2009.0001). Fasting overall appetite suppression scores were improved with semaglutide vs placebo, while nausea ratings were similar. Semaglutide was associated with less hunger and food cravings, better control of eating and a lower preference for high\u2010fat foods. Resting metabolic rate, adjusted for lean body mass, did not differ between treatments. Semaglutide led to a reduction from baseline in mean body weight of 5.0\u2009kg, predominantly from body fat mass.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>\n                      After 12\u2009weeks of treatment,\n                      <jats:italic>ad libitum<\/jats:italic>\n                      energy intake was substantially lower with semaglutide vs placebo with a corresponding loss of body weight observed with semaglutide. In addition to reduced energy intake, likely mechanisms for semaglutide\u2010induced weight loss included less appetite and food cravings, better control of eating and lower relative preference for fatty, energy\u2010dense foods.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Video Abstract<\/jats:title>\n                    <jats:p>\n                      A free Video Abstract to accompany this article is available at:\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"https:\/\/player.vimeo.com\/video\/218478638\">https:\/\/player.vimeo.com\/video\/218478638<\/jats:ext-link>\n                      .\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/dom.12932","type":"journal-article","created":{"date-parts":[[2017,3,7]],"date-time":"2017-03-07T06:46:40Z","timestamp":1488869200000},"page":"1242-1251","source":"Crossref","is-referenced-by-count":653,"title":["Effects of once\u2010weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity"],"prefix":"10.1111","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7085-9596","authenticated-orcid":false,"given":"John","family":"Blundell","sequence":"first","affiliation":[{"name":"Department of Psychology University of Leeds  Leeds UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Graham","family":"Finlayson","sequence":"additional","affiliation":[{"name":"Department of Psychology University of Leeds  Leeds UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mads","family":"Axelsen","sequence":"additional","affiliation":[{"name":"Novo Nordisk  S\u00f8borg Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Flint","sequence":"additional","affiliation":[{"name":"Novo Nordisk  S\u00f8borg Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Gibbons","sequence":"additional","affiliation":[{"name":"Department of Psychology University of Leeds  Leeds UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Trine","family":"Kvist","sequence":"additional","affiliation":[{"name":"Novo Nordisk  S\u00f8borg Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie B.","family":"Hjerpsted","sequence":"additional","affiliation":[{"name":"Novo Nordisk  S\u00f8borg Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2017,5,5]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1210\/edrv.20.6.0385"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.2337\/dcS13-2015"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI990"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1152\/ajpregu.1999.276.5.R1541"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.6326-11.2012"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc08-1355"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-5491.2009.02666.x"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc14-1630"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1411892"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1038\/ijo.2013.162"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.2337\/db14-0849"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI72434"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.5b00726"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.443"},{"issue":"1","key":"e_1_2_6_16_1","first-page":"S358","article-title":"Pharmacokinetics and tolerability of a single dose of semaglutide, a once\u2010weekly human GLP\u20101 analogue, in subjects with and without renal impairment","volume":"57","author":"Marbury T","year":"2014","journal-title":"Diabetologia"},{"key":"e_1_2_6_17_1","first-page":"e22","article-title":"Effect of medication dosing frequency on adherence in chronic diseases","volume":"15","author":"Saini SD","year":"2009","journal-title":"Am J Manag Care"},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1463-1326.2010.01327.x"},{"key":"e_1_2_6_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1463-1326.2011.01357.x"},{"key":"e_1_2_6_20_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc15-0165"},{"key":"e_1_2_6_21_1","unstructured":"European Agency for the Evaluation of Medicinal Products.International Conference on Harmonisation\u2010World Health Organization Guideline for Good Clinical Practice [EMEA Web site] ICH Harmonised tripartite guideline good clinical practice.http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Scientific_guideline\/2009\/09\/WC500002874.pdf. Accessed January 11 2016."},{"key":"e_1_2_6_22_1","unstructured":"World Medical Association. Declaration of Helsinki ethical principles for medical research involving human subjects.52nd WMA General Assembly; October2000;Edinburgh Scotland. Last amended with Note of Clarification on Paragraph 29 by the WMA General Assembly; Washington 2002; and Note of Clarification on Paragraph 30 by the WMA General Assembly; Tokyo 2004.http:\/\/www.wma.net\/en\/30publications\/10policies\/b3\/index.html.pdf. Accessed January 14 2016."},{"key":"e_1_2_6_23_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.ijo.0801083"},{"key":"e_1_2_6_24_1","doi-asserted-by":"publisher","DOI":"10.1088\/0967-3334\/17\/1\/005"},{"key":"e_1_2_6_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/0195-6663(91)90021-J"},{"key":"e_1_2_6_26_1","doi-asserted-by":"publisher","DOI":"10.1038\/ejcn.2015.57"},{"key":"e_1_2_6_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.appet.2007.06.007"},{"key":"e_1_2_6_28_1","doi-asserted-by":"publisher","DOI":"10.3945\/jn.111.148106"},{"key":"e_1_2_6_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.appet.2011.08.012"},{"key":"e_1_2_6_30_1","doi-asserted-by":"publisher","DOI":"10.1017\/S0007114510000838"},{"key":"e_1_2_6_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.appet.2010.09.018"},{"key":"e_1_2_6_32_1","doi-asserted-by":"publisher","DOI":"10.1093\/ajcn\/75.3.453"},{"key":"e_1_2_6_33_1","doi-asserted-by":"publisher","DOI":"10.1038\/oby.2005.146"},{"key":"e_1_2_6_34_1","volume-title":"Techniques for Measuring Body Composition","author":"Siri W","year":"1961"},{"key":"e_1_2_6_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(11)60812-X"},{"key":"e_1_2_6_36_1","doi-asserted-by":"publisher","DOI":"10.1038\/ijo.2013.51"},{"key":"e_1_2_6_37_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1105816"},{"issue":"1","key":"e_1_2_6_38_1","first-page":"1119","article-title":"In vivo effect of semaglutide in pigs supports its potential as a long\u2010acting GLP\u20101 analogue for once\u2010weekly dosing","volume":"64","author":"Rolin B","year":"2015","journal-title":"Diabetes"},{"key":"e_1_2_6_39_1","doi-asserted-by":"publisher","DOI":"10.1152\/ajpendo.2001.281.1.E155"},{"key":"e_1_2_6_40_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2012.02.016"},{"key":"e_1_2_6_41_1","article-title":"Semaglutide and cardiovascular outcomes in patients with type 2 diabetes","author":"Marso SP","year":"2016","journal-title":"N Engl J Med"}],"container-title":["Diabetes, Obesity and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fdom.12932","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/dom.12932","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/dom.12932","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/dom-pubs.pericles-prod.literatumonline.com\/doi\/pdf\/10.1111\/dom.12932","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T02:35:35Z","timestamp":1761878135000},"score":1,"resource":{"primary":{"URL":"https:\/\/dom-pubs.pericles-prod.literatumonline.com\/doi\/10.1111\/dom.12932"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5,5]]},"references-count":40,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2017,9]]}},"alternative-id":["10.1111\/dom.12932"],"URL":"https:\/\/doi.org\/10.1111\/dom.12932","archive":["Portico"],"relation":{},"ISSN":["1462-8902","1463-1326"],"issn-type":[{"value":"1462-8902","type":"print"},{"value":"1463-1326","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,5,5]]}}}